Accelerating Antibody Drug Development With Affinity Purification

The changing landscape for antibody-derived therapeutics, such as bi-specific monoclonal antibodies, Fab fragments and Fc-fusion proteins brings new purification challenges in the downstream processing of these molecules. Standard chromatography resins, such as Protein A, may not result in the most efficient purification process.

Download this poster to discover a subdomain-specific affinity solution that:

• Provides unique selectivity 
• Delivers high target purity and yields in a single step
• Addresses key purification challenges in therapeutic antibody development